Last 12 months
Inside the activity.
0 purchase rows · 0 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 25, 2021 Filed Oct 26, 2021 21:08 UTC |
Peterson CarynEVP, Regulatory Affairs
|
SaleCommon Stock | 2,377 | $12.25 | $29,118.25 |
DisclosureSEC source: 0001728117-21-000100 · wf-form4_163528246970845.xml · nonDerivative · entry 1 Peterson Caryn · CIK 0001857256 · EVP, Regulatory Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,451 F1 · shares: Represents a broker-assisted sale to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of restricted stock units. Read SEC document |
| October 25, 2021 Filed Oct 26, 2021 20:58 UTC |
Aranda RichardChief Medical Officer
|
SaleCommon Stock | 2,377 | $12.25 | $29,118.25 |
DisclosureSEC source: 0001728117-21-000096 · wf-form4_163528190028614.xml · nonDerivative · entry 1 Aranda Richard · CIK 0001867872 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 217,432 F1 · shares: Represents a broker-assisted sale to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of restricted stock units. Read SEC document |
| September 16, 2021 Filed Sep 20, 2021 20:25 UTC |
Giraudo BryanCOO/CFO
|
GrantStock Option (Right to Buy) · Derivative | 150,000 | $0.00 Strike: $10.54 | $0.00 |
DisclosureSEC source: 0001728117-21-000091 · wf-form4_163216948450731.xml · derivative · entry 1 Giraudo Bryan · CIK 0001740847 · COO/CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2031-09-16 F1 · derivative.exercise_date: 25% of the total number of shares subject to the option will vest on September 16, 2022 and 1/48th of the total number of shares subject to the option vest on the last day of each one-month period thereafter, subject to the Reporting Person's continuous service to the Corporation on each such vesting date Read SEC document |
| June 30, 2021 Filed Jul 1, 2021 16:02 UTC |
Carter LauraChief Scientific Officer
|
GrantCommon Stock | 25,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001728117-21-000080 · wf-form4_162516967007694.xml · nonDerivative · entry 1 Carter Laura · CIK 0001858178 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,683 F1 · shares: Represents a restricted stock unit award, which will vest on the first anniversary of the grant date in accordance with the terms of the award and subject to the Reporting Person's continuous service to the Issuer on such vesting date. Read SEC document |
| June 21, 2021 Filed Jun 23, 2021 00:13 UTC |
Aranda RichardChief Medical Officer
|
GrantStock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $8.47 | $0.00 |
DisclosureSEC source: 0001728117-21-000078 · wf-form4_162440717118673.xml · derivative · entry 2 Aranda Richard · CIK 0001867872 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2031-06-21 F2 · derivative.exercise_date: 25% of the total number of shares subject to the option will vest on June 21, 2022 and 1/48th of the total number of shares subject to the option vest on the last day of each one-month period thereafter, subject to the Reporting Person's continuous service to the Issuer on each such vesting date. Read SEC document |
| June 21, 2021 Filed Jun 23, 2021 00:13 UTC |
Aranda RichardChief Medical Officer
|
GrantCommon Stock | 15,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001728117-21-000078 · wf-form4_162440717118673.xml · nonDerivative · entry 1 Aranda Richard · CIK 0001867872 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 219,809 F1 · shares: Represents a restricted stock unit award, which will vest in three equal annual installments in accordance with the terms of the award and subject to the Reporting Person's continuous service to the Issuer on each vesting date. Read SEC document |
| June 10, 2021 Filed Jun 14, 2021 21:26 UTC |
Milligan SandraDirector
|
GrantStock Option (Right to Buy) · Derivative | 47,000 | $0.00 Strike: $8.93 | $0.00 |
DisclosureSEC source: 0001728117-21-000074 · wf-form4_162370598998133.xml · derivative · entry 1 Milligan Sandra · CIK 0001859810 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,000 Underlying: Common Stock · 47,000 shares Expires 2031-06-09 F1 · derivative.exercise_date: 1/36th of the total number of shares subject to the option vest on the last day of each one-month period thereafter, subject to the Reporting Person's continuous service to the Corporation on each such vesting date. Read SEC document |
| June 09, 2021 Filed Jun 11, 2021 01:41 UTC |
Bilenker Joshua H.Director
|
GrantStock Option (Right to Buy) · Derivative | 23,500 | $0.00 Strike: $8.97 | $0.00 |
DisclosureSEC source: 0001728117-21-000068 · wf-form4_162337569513720.xml · derivative · entry 1 Bilenker Joshua H. · CIK 0001612312 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,500 Underlying: Common Stock · 23,500 shares Expires 2031-06-08 F1 · derivative.exercise_date: The entire number of shares subject to this option becomes fully vested and exercisable on the first to occur of (a) the first anniversary of the grant date or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date. Read SEC document |
| June 09, 2021 Filed Jun 10, 2021 23:49 UTC |
Cox Russell J.Director
|
GrantStock Option (Right to Buy) · Derivative | 23,500 | $0.00 Strike: $8.97 | $0.00 |
DisclosureSEC source: 0001728117-21-000058 · wf-form4_162336895818140.xml · derivative · entry 1 Cox Russell J. · CIK 0001512984 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,500 Underlying: Common Stock · 23,500 shares Expires 2031-06-08 F1 · derivative.exercise_date: The entire number of shares subject to this option becomes fully vested and exercisable on the first to occur of (a) the first anniversary of the grant date or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date. Read SEC document |
| June 09, 2021 Filed Jun 10, 2021 23:54 UTC |
Daniel Thomas ODirector
|
GrantStock Option (Right to Buy) · Derivative | 23,500 | $0.00 Strike: $8.97 | $0.00 |
DisclosureSEC source: 0001728117-21-000064 · wf-form4_162336924416710.xml · derivative · entry 1 Daniel Thomas O · CIK 0001538894 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,500 Underlying: Common Stock · 23,500 shares Expires 2031-06-08 F1 · derivative.exercise_date: The entire number of shares subject to this option becomes fully vested and exercisable on the first to occur of (a) the first anniversary of the grant date or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date. Read SEC document |
| June 09, 2021 Filed Jun 11, 2021 01:01 UTC |
Burow KristinaDirector
|
GrantStock Option (Right to Buy) · Derivative | 23,500 | $0.00 Strike: $8.97 | $0.00 |
DisclosureSEC source: 0001728117-21-000066 · wf-form4_162337324957986.xml · derivative · entry 1 Burow Kristina · CIK 0001569248 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,500 Underlying: Common Stock · 23,500 shares Expires 2031-06-08 F1 · derivative.exercise_date: The entire number of shares subject to this option becomes fully vested and exercisable on the first to occur of (a) the first anniversary of the grant date or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date. Read SEC document |
| June 09, 2021 Filed Jun 10, 2021 23:52 UTC |
GALA RENEE DDirector
|
GrantStock Option (Right to Buy) · Derivative | 23,500 | $0.00 Strike: $8.97 | $0.00 |
DisclosureSEC source: 0001728117-21-000061 · wf-form4_162336911267661.xml · derivative · entry 1 GALA RENEE D · CIK 0001607737 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,500 Underlying: Common Stock · 23,500 shares Expires 2031-06-08 F1 · derivative.exercise_date: The entire number of shares subject to this option becomes fully vested and exercisable on the first to occur of (a) the first anniversary of the grant date or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date. Read SEC document |
| May 03, 2021 Filed May 5, 2021 17:15 UTC |
Carter LauraChief Scientific Officer
|
GrantStock Option (Right to Buy) · Derivative | 31,750 | $0.00 Strike: $8.70 | $0.00 |
DisclosureSEC source: 0001728117-21-000050 · wf-form4_162024930008740.xml · derivative · entry 2 Carter Laura · CIK 0001858178 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,750 Underlying: Common Stock · 31,750 shares Expires 2031-05-03 F2 · derivative.exercise_date: 25% of the total number of shares subject to the option will vest on May 3, 2022 and 1/48th of the total number of shares subject to the option vest on the last day of each one-month period thereafter, subject to the Reporting Person's continuous service to the Issuer on each such vesting date. Read SEC document |
| May 03, 2021 Filed May 5, 2021 17:15 UTC |
Carter LauraChief Scientific Officer
|
GrantCommon Stock | 10,820 | $0.00 | $0.00 |
DisclosureSEC source: 0001728117-21-000050 · wf-form4_162024930008740.xml · nonDerivative · entry 1 Carter Laura · CIK 0001858178 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,683 F1 · shares: Represents a restricted stock unit award, which will vest in three equal annual installments in accordance with the terms of the award and subject to the Reporting Person's continuous service to the Issuer on each vesting date. Read SEC document |
| April 16, 2021 Filed Apr 20, 2021 22:07 UTC |
Peterson CarynEVP, Regulatory Affairs
|
GrantStock Option (Right to Buy) · Derivative | 31,750 | $0.00 Strike: $8.49 | $0.00 |
DisclosureSEC source: 0001728117-21-000040 · wf-form4_161895639999354.xml · derivative · entry 2 Peterson Caryn · CIK 0001857256 · EVP, Regulatory Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,750 Underlying: Common Stock · 31,750 shares Expires 2031-04-16 F2 · derivative.exercise_date: 25% of the total number of shares subject to the option will vest on April 16, 2022 and 1/48th of the total number of shares subject to the option vest on the last day of each one-month period thereafter, subject to the Reporting Person's continuous service to the Issuer on each such vesting date. Read SEC document |
| April 16, 2021 Filed Apr 20, 2021 22:07 UTC |
Peterson CarynEVP, Regulatory Affairs
|
GrantCommon Stock | 10,820 | $0.00 | $0.00 |
DisclosureSEC source: 0001728117-21-000040 · wf-form4_161895639999354.xml · nonDerivative · entry 1 Peterson Caryn · CIK 0001857256 · EVP, Regulatory Affairs 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,828 F1 · shares: Represents a restricted stock unit award, which will vest in three equal annual installments in accordance with the terms of the award and subject to the Reporting Person's continuous service to the Issuer on each vesting date. Read SEC document |
| March 23, 2021 Filed Mar 25, 2021 20:09 UTC |
Christian WaageEVP & General Counsel
|
SaleCommon Stock | 5,490 | $9.48 | $52,050.69 |
DisclosureSEC source: 0001728117-21-000029 · wf-form4_161670295456273.xml · nonDerivative · entry 1 Christian Waage · CIK 0001553179 · EVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 588,199 F1 · shares: Represents a broker-assisted sale to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of restricted stock units. Read SEC document |
| March 23, 2021 Filed Mar 25, 2021 20:13 UTC |
Salter-Cid LuisaChief Scientific Officer
|
SaleCommon Stock | 5,491 | $9.48 | $52,051.93 |
DisclosureSEC source: 0001728117-21-000033 · wf-form4_161670321781288.xml · nonDerivative · entry 1 Salter-Cid Luisa · CIK 0001766404 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 206,065 F1 · shares: Represents a broker-assisted sale to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of restricted stock units. Read SEC document |
| March 23, 2021 Filed Mar 25, 2021 20:11 UTC |
Giraudo BryanChief Financial Officer
|
SaleCommon Stock | 5,490 | $9.48 | $52,045.75 |
DisclosureSEC source: 0001728117-21-000031 · wf-form4_161670308383086.xml · nonDerivative · entry 1 Giraudo Bryan · CIK 0001740847 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 109,889 F1 · shares: Represents a broker-assisted sale to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of restricted stock units. Read SEC document |
| February 25, 2021 Filed Mar 2, 2021 00:40 UTC |
Hasnain FaheemDirector · President & CEO
|
GrantStock Option (Right to Buy) · Derivative | 325,000 | $0.00 Strike: $9.79 | $0.00 |
DisclosureSEC source: 0001728117-21-000027 · wf-form4_161464558623631.xml · derivative · entry 3 Hasnain Faheem · CIK 0001352620 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 325,000 Underlying: Common Stock · 325,000 shares Expires 2031-02-25 F3 · derivative.exercise_date: 25% of the total number of shares subject to the option will vest on February 25, 2022 and 1/48th of the total number of shares subject to the option vest on the last day of each one-month period thereafter, subject to the Reporting Person's continuous service to the Issuer on each such vesting date. Read SEC document |
| February 25, 2021 Filed Mar 2, 2021 00:40 UTC |
Hasnain FaheemDirector · President & CEO
|
GrantCommon Stock | 162,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001728117-21-000027 · wf-form4_161464558623631.xml · nonDerivative · entry 1 Hasnain Faheem · CIK 0001352620 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 162,500 F1 · shares: Represents restricted stock unit award, which will vest in three equal annual installments in accordance with the terms of the award and subject to the Reporting Person's continuous service to the Issuer on each vesting date. Read SEC document |
| February 25, 2021 Filed Mar 1, 2021 21:37 UTC |
Christian WaageEVP & General Counsel
|
GrantStock Option (Right to Buy) · Derivative | 90,000 | $0.00 Strike: $9.79 | $0.00 |
DisclosureSEC source: 0001728117-21-000021 · wf-form4_161463460466974.xml · derivative · entry 4 Christian Waage · CIK 0001553179 · EVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,000 Underlying: Common Stock · 90,000 shares Expires 2031-02-25 F3 · derivative.exercise_date: 25% of the total number of shares subject to the option will vest on February 25, 2022 and 1/48th of the total number of shares subject to the option vest on the last day of each one-month period thereafter, subject to the Reporting Person's continuous service to the Issuer on each such vesting date. Read SEC document |
| February 25, 2021 Filed Mar 1, 2021 21:37 UTC |
Christian WaageEVP & General Counsel
|
GrantCommon Stock | 45,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001728117-21-000021 · wf-form4_161463460466974.xml · nonDerivative · entry 1 Christian Waage · CIK 0001553179 · EVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 593,689 F1 · shares: Represents restricted stock unit award, which will vest in three equal annual installments in accordance with the terms of the award and subject to the Reporting Person's continuous service to the Issuer on each vesting date. F2 · balance_after: Includes 97,923 shares subject to forfeiture, which shares will vest in equal monthly installments as set forth in the restricted stock agreement between the Issuer and Reporting Person so that all of the shares will be released from the forfeiture restriction on November 18, 2021, subject to the Reporting Person's continuous service to the Issuer on each such vesting date. Also includes 46,500 restricted stock units granted in February 2020, which shares will vest in three equal annual installments in accordance with the terms of the award and subject to the Reporting Person's continuous service to the Issuer on each vesting date. Read SEC document |
| February 25, 2021 Filed Mar 1, 2021 21:54 UTC |
Salter-Cid LuisaChief Scientific Officer
|
GrantStock Option (Right to Buy) · Derivative | 90,000 | $0.00 Strike: $9.79 | $0.00 |
DisclosureSEC source: 0001728117-21-000025 · wf-form4_161463558108922.xml · derivative · entry 2 Salter-Cid Luisa · CIK 0001766404 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,000 Underlying: Common Stock · 90,000 shares Expires 2031-02-25 F3 · derivative.exercise_date: 25% of the total number of shares subject to the option will vest on February 25, 2022 and 1/48th of the total number of shares subject to the option vest on the last day of each one-month period thereafter, subject to the Reporting Person's continuous service to the Issuer on each such vesting date. Read SEC document |
| February 25, 2021 Filed Mar 1, 2021 21:54 UTC |
Salter-Cid LuisaChief Scientific Officer
|
GrantCommon Stock | 45,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001728117-21-000025 · wf-form4_161463558108922.xml · nonDerivative · entry 1 Salter-Cid Luisa · CIK 0001766404 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 211,556 F1 · shares: Represents restricted stock unit award, which will vest in three equal annual installments in accordance with the terms of the award and subject to the Reporting Person's continuous service to the Issuer on each vesting date. F2 · balance_after: Includes 32,641 shares subject to forfeiture, which shares will vest in equal monthly installments as set forth in the restricted stock agreement between the Issuer and Reporting Person so that all of the shares will be released from the forfeiture restriction on November 18, 2021, subject to the Reporting Person's continuous service to the Issuer on each such vesting date. Also includes 46,500 restricted stock units granted in February 2020, which shares will vest in three equal annual installments in accordance with the terms of the award and subject to the Reporting Person's continuous service to the Issuer on each vesting date. Read SEC document |
| February 25, 2021 Filed Mar 1, 2021 21:50 UTC |
Giraudo BryanChief Financial Officer
|
GrantStock Option (Right to Buy) · Derivative | 90,000 | $0.00 Strike: $9.79 | $0.00 |
DisclosureSEC source: 0001728117-21-000023 · wf-form4_161463539991270.xml · derivative · entry 3 Giraudo Bryan · CIK 0001740847 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,000 Underlying: Common Stock · 90,000 shares Expires 2031-02-25 F3 · derivative.exercise_date: 25% of the total number of shares subject to the option will vest on February 25, 2022 and 1/48th of the total number of shares subject to the option vest on the last day of each one-month period thereafter, subject to the Reporting Person's continuous service to the Issuer on each such vesting date. Read SEC document |
| February 25, 2021 Filed Mar 1, 2021 21:50 UTC |
Giraudo BryanChief Financial Officer
|
GrantCommon Stock | 45,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001728117-21-000023 · wf-form4_161463539991270.xml · nonDerivative · entry 1 Giraudo Bryan · CIK 0001740847 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 115,379 F1 · shares: Represents restricted stock unit award, which will vest in three equal annual installments in accordance with the terms of the award and subject to the Reporting Person's continuous service to the Issuer on each vesting date. F2 · balance_after: Includes 46,500 restricted stock units granted in February 2020, which shares will vest in three equal annual installments in accordance with the terms of the award and subject to the Reporting Person's continuous service to the Issuer on each vesting date. Read SEC document |
| October 14, 2020 Filed Oct 14, 2020 23:28 UTC |
Hasnain FaheemDirector
|
PurchaseCommon Stock | 96,520 | $10.36 | $999,995.46 |
DisclosureSEC source: 0001209191-20-054841 · doc4.xml · nonDerivative · entry 1 Hasnain Faheem · CIK 0001352620 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By family trust Disclosed balance after: 3,478,629 F1 · price: This transaction was executed in multiple trades at prices ranging from $10.00 to $10.55 per share. The price reported above reflects the weighted average sale price for the entire number of shares purchased. Information on the exact number of shares purchased at each sale price can be obtained from the Issuer upon request. F2 · balance_after: Includes 1,491,103 shares subject to forfeiture, which shares will vest in equal monthly installments as set forth in the restricted stock agreements between the Issuer and Reporting Person so that all of the shares will be released from the forfeiture restriction on January 4, 2023, subject to the Reporting Person's continuous service to the Issuer on each such vesting date. Read SEC document |
| October 14, 2020 Filed Oct 14, 2020 23:29 UTC |
Christian WaageEVP & General Counsel
|
PurchaseCommon Stock | 2,500 | $9.53 | $23,818.00 |
DisclosureSEC source: 0001209191-20-054842 · doc4.xml · nonDerivative · entry 1 Christian Waage · CIK 0001553179 · EVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Indirect · By family trust Disclosed balance after: 6,954 F1 · price: This transaction was executed in multiple trades at prices ranging from $9.52 to $9.53 per share. The price reported above reflects the weighted average sale price for the entire number of shares purchased. Information on the exact number of shares purchased at each sale price can be obtained from the Issuer upon request. Read SEC document |
| October 14, 2020 Filed Oct 14, 2020 23:27 UTC |
Giraudo BryanChief Financial Officer
|
PurchaseCommon Stock | 3,000 | $10.01 | $30,036.00 |
DisclosureSEC source: 0001209191-20-054839 · doc4.xml · nonDerivative · entry 1 Giraudo Bryan · CIK 0001740847 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By family trust Disclosed balance after: 7,121 F1 · price: This transaction was executed in multiple trades at prices ranging from $9.41 to $10.31 per share. The price reported above reflects the weighted average sale price for the entire number of shares purchased. Information on the exact number of shares purchased at each sale price can be obtained from the Issuer upon request. Read SEC document |
| June 23, 2020 Filed Jun 23, 2020 21:01 UTC |
Giraudo BryanChief Financial Officer
|
PurchaseCommon Stock | 2,000 | $12.96 | $25,922.40 |
DisclosureSEC source: 0001209191-20-038515 · doc4.xml · nonDerivative · entry 1 Giraudo Bryan · CIK 0001740847 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By family trust Disclosed balance after: 4,121 F1 · price: This transaction was executed in multiple trades at prices ranging from $12.9606 to $12.962 per share. The price reported above reflects the weighted average sale price for the entire number of shares purchased. Information on the exact number of shares purchased at each sale price can be obtained from the Issuer upon request. Read SEC document |
| June 17, 2020 Filed Jun 18, 2020 20:52 UTC |
Bilenker Joshua H.Director
|
GrantStock Option (right to buy) · Derivative | 23,500 | $0.00 Strike: $12.10 | $0.00 |
DisclosureSEC source: 0001209191-20-037635 · doc4.xml · derivative · entry 1 Bilenker Joshua H. · CIK 0001612312 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,500 Underlying: Common Stock · 23,500 shares Expires 2030-06-16 F1 · derivative.exercise_date: The entire number of shares subject to this option becomes fully vested and exercisable on the first to occur of (a) the first anniversary of the grant date or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date. Read SEC document |
| June 17, 2020 Filed Jun 18, 2020 20:51 UTC |
Hasnain FaheemDirector
|
GrantStock Option (right to buy) · Derivative | 47,000 | $0.00 Strike: $12.10 | $0.00 |
DisclosureSEC source: 0001209191-20-037633 · doc4.xml · derivative · entry 1 Hasnain Faheem · CIK 0001352620 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,000 Underlying: Common Stock · 47,000 shares Expires 2030-06-16 F1 · derivative.exercise_date: The entire number of shares subject to this option becomes fully vested and exercisable on the first to occur of (a) the first anniversary of the grant date or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date. Read SEC document |
| June 17, 2020 Filed Jun 18, 2020 20:57 UTC |
Cox Russell J.Director
|
GrantStock Option (right to buy) · Derivative | 23,500 | $0.00 Strike: $12.10 | $0.00 |
DisclosureSEC source: 0001209191-20-037640 · doc4.xml · derivative · entry 1 Cox Russell J. · CIK 0001512984 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,500 Underlying: Common Stock · 23,500 shares Expires 2030-06-16 F1 · derivative.exercise_date: The entire number of shares subject to this option becomes fully vested and exercisable on the first to occur of (a) the first anniversary of the grant date or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date. Read SEC document |
| June 17, 2020 Filed Jun 18, 2020 20:59 UTC |
Daniel Thomas ODirector
|
GrantStock Option (right to buy) · Derivative | 23,500 | $0.00 Strike: $12.10 | $0.00 |
DisclosureSEC source: 0001209191-20-037644 · doc4.xml · derivative · entry 1 Daniel Thomas O · CIK 0001538894 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,500 Underlying: Common Stock · 23,500 shares Expires 2030-06-16 F1 · derivative.exercise_date: The entire number of shares subject to this option becomes fully vested and exercisable on the first to occur of (a) the first anniversary of the grant date or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date. Read SEC document |
| June 17, 2020 Filed Jun 18, 2020 20:55 UTC |
Burow KristinaDirector
|
GrantStock Option (right to buy) · Derivative | 23,500 | $0.00 Strike: $12.10 | $0.00 |
DisclosureSEC source: 0001209191-20-037638 · doc4.xml · derivative · entry 1 Burow Kristina · CIK 0001569248 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,500 Underlying: Common Stock · 23,500 shares Expires 2030-06-16 F1 · derivative.exercise_date: The entire number of shares subject to this option becomes fully vested and exercisable on the first to occur of (a) the first anniversary of the grant date or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date. Read SEC document |
| June 17, 2020 Filed Jun 18, 2020 21:22 UTC |
GALA RENEE DDirector
|
GrantStock Option (right to buy) · Derivative | 23,500 | $0.00 Strike: $12.10 | $0.00 |
DisclosureSEC source: 0001209191-20-037679 · doc4.xml · derivative · entry 1 GALA RENEE D · CIK 0001607737 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,500 Underlying: Common Stock · 23,500 shares Expires 2030-06-16 F1 · derivative.exercise_date: The entire number of shares subject to this option becomes fully vested and exercisable on the first to occur of (a) the first anniversary of the grant date or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date. Read SEC document |
| February 14, 2020 Filed Feb 19, 2020 21:23 UTC |
Dupont JakobChief Medical Officer
|
GrantStock Option (right to buy) · Derivative | 71,500 | $0.00 Strike: $14.55 | $0.00 |
DisclosureSEC source: 0001209191-20-010521 · doc4.xml · derivative · entry 2 Dupont Jakob · CIK 0001553335 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,500 Underlying: Common Stock · 71,500 shares Expires 2030-02-14 F2 · derivative.exercise_date: 25% of the total number of shares subject to the option will vest on February 14, 2021 and 1/48th of the total number of shares subject to the option vest on the last day of each one-month period thereafter, subject to the Reporting Person's continuous service to the Issuer on each such vesting date. Read SEC document |
| February 14, 2020 Filed Feb 19, 2020 21:23 UTC |
Dupont JakobChief Medical Officer
|
GrantCommon Stock | 46,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-010521 · doc4.xml · nonDerivative · entry 1 Dupont Jakob · CIK 0001553335 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,500 F1 · shares: Represents restricted stock unit award, which will vest in three equal annual installments in accordance with the terms of the award and subject to the Reporting Person's continuous service to the Issuer on each vesting date. Read SEC document |
| February 14, 2020 Filed Feb 19, 2020 21:21 UTC |
Christian WaageEVP & General Counsel
|
GrantStock Option (right to buy) · Derivative | 71,500 | $0.00 Strike: $14.55 | $0.00 |
DisclosureSEC source: 0001209191-20-010517 · doc4.xml · derivative · entry 4 Christian Waage · CIK 0001553179 · EVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,500 Underlying: Common Stock · 71,500 shares Expires 2030-02-14 F3 · derivative.exercise_date: 25% of the total number of shares subject to the option will vest on February 14, 2021 and 1/48th of the total number of shares subject to the option vest on the last day of each one-month period thereafter, subject to the Reporting Person's continuous service to the Issuer on each such vesting date. Read SEC document |
| February 14, 2020 Filed Feb 19, 2020 21:21 UTC |
Christian WaageEVP & General Counsel
|
GrantCommon Stock | 46,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-010517 · doc4.xml · nonDerivative · entry 1 Christian Waage · CIK 0001553179 · EVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 547,998 F1 · shares: Represents restricted stock unit award, which will vest in three equal annual installments in accordance with the terms of the award and subject to the Reporting Person's continuous service to the Issuer on each vesting date. F2 · balance_after: Includes 228,459 shares subject to forfeiture, which shares will vest in equal monthly installments as set forth in the restricted stock agreement between the Issuer and Reporting Person so that all of the shares will be released from the forfeiture restriction on November 18, 2021, subject to the Reporting Person's continuous service to the Issuer on each such vesting date. Read SEC document |
| February 14, 2020 Filed Feb 19, 2020 21:18 UTC |
GUJRATHI SHEILADirector · President & CEO
|
GrantStock Option (right to buy) · Derivative | 292,000 | $0.00 Strike: $14.55 | $0.00 |
DisclosureSEC source: 0001209191-20-010512 · doc4.xml · derivative · entry 3 Gujrathi Sheila · CIK 0001575202 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 292,000 Underlying: Common Stock · 292,000 shares Expires 2030-02-14 F3 · derivative.exercise_date: 25% of the total number of shares subject to the option will vest on February 14, 2021 and 1/48th of the total number of shares subject to the option vest on the last day of each one-month period thereafter, subject to the Reporting Person's continuous service to the Issuer on each such vesting date. Read SEC document |
| February 14, 2020 Filed Feb 19, 2020 21:18 UTC |
GUJRATHI SHEILADirector · President & CEO
|
GrantCommon Stock | 189,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-010512 · doc4.xml · nonDerivative · entry 1 Gujrathi Sheila · CIK 0001575202 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 189,500 F1 · shares: Represents restricted stock unit award, which will vest in three equal annual installments in accordance with the terms of the award and subject to the Reporting Person's continuous service to the Issuer on each vesting date. Read SEC document |
| February 14, 2020 Filed Feb 19, 2020 21:21 UTC |
Salter-Cid LuisaChief Scientific Officer
|
GrantStock Option (right to buy) · Derivative | 71,500 | $0.00 Strike: $14.55 | $0.00 |
DisclosureSEC source: 0001209191-20-010519 · doc4.xml · derivative · entry 2 Salter-Cid Luisa · CIK 0001766404 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,500 Underlying: Common Stock · 71,500 shares Expires 2030-02-14 F3 · derivative.exercise_date: 25% of the total number of shares subject to the option will vest on February 14, 2021 and 1/48th of the total number of shares subject to the option vest on the last day of each one-month period thereafter, subject to the Reporting Person's continuous service to the Issuer on each such vesting date. Read SEC document |
| February 14, 2020 Filed Feb 19, 2020 21:21 UTC |
Salter-Cid LuisaChief Scientific Officer
|
GrantCommon Stock | 46,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-010519 · doc4.xml · nonDerivative · entry 1 Salter-Cid Luisa · CIK 0001766404 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 166,556 F1 · shares: Represents restricted stock unit award, which will vest in three equal annual installments in accordance with the terms of the award and subject to the Reporting Person's continuous service to the Issuer on each vesting date. F2 · balance_after: Includes 76,153 shares subject to forfeiture, which shares will vest in equal monthly installments as set forth in the restricted stock agreement between the Issuer and Reporting Person so that all of the shares will be released from the forfeiture restriction on November 18, 2021, subject to the Reporting Person's continuous service to the Issuer on each such vesting date. Read SEC document |
| February 14, 2020 Filed Feb 19, 2020 21:20 UTC |
Giraudo BryanChief Financial Officer
|
GrantStock Option (right to buy) · Derivative | 71,500 | $0.00 Strike: $14.55 | $0.00 |
DisclosureSEC source: 0001209191-20-010515 · doc4.xml · derivative · entry 3 Giraudo Bryan · CIK 0001740847 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,500 Underlying: Common Stock · 71,500 shares Expires 2030-02-14 F2 · derivative.exercise_date: 25% of the total number of shares subject to the option will vest on February 14, 2021 and 1/48th of the total number of shares subject to the option vest on the last day of each one-month period thereafter, subject to the Reporting Person's continuous service to the Issuer on each such vesting date. Read SEC document |
| February 14, 2020 Filed Feb 19, 2020 21:20 UTC |
Giraudo BryanChief Financial Officer
|
GrantCommon Stock | 46,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-010515 · doc4.xml · nonDerivative · entry 1 Giraudo Bryan · CIK 0001740847 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,379 F1 · shares: Represents restricted stock unit award, which will vest in three equal annual installments in accordance with the terms of the award and subject to the Reporting Person's continuous service to the Issuer on each vesting date. Read SEC document |
| December 31, 2019 Filed Jan 2, 2020 22:00 UTC |
Salter-Cid LuisaChief Scientific Officer
|
GiftCommon Stock | 4,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-000367 · doc4.xml · nonDerivative · entry 1 Salter-Cid Luisa · CIK 0001766404 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,056 Read SEC document |
| December 30, 2019 Filed Dec 31, 2019 22:00 UTC |
Dupont JakobChief Medical Officer
|
Exercise / conversionNon-qualified stock option (Right to Buy) · Derivative | 40,000 | $0.00 Strike: $10.71 | $0.00 |
DisclosureSEC source: 0001209191-19-062303 · doc4.xml · derivative · entry 6 Dupont Jakob · CIK 0001553335 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 439,317 Underlying: Common Stock · 40,000 shares Expires 2028-12-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The option was granted on December 14, 2018. 25% of the total number of shares subject to the option vested on December 14, 2019 and 1/48th of the total number of shares subject to the option vest on the last day of each one-month period thereafter, subject to the Reporting Person's continuous service to the Corporation on each such vesting date. Read SEC document |
| December 30, 2019 Filed Dec 31, 2019 22:00 UTC |
Dupont JakobChief Medical Officer
|
SaleCommon Stock | 40,000 | $15.00 | $600,004.00 |
DisclosureSEC source: 0001209191-19-062303 · doc4.xml · nonDerivative · entry 4 Dupont Jakob · CIK 0001553335 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.